Clostridium Difficile Infection Pipeline Expands with New Treatments
A new analysis report reveals over 20 companies are developing novel treatments for Clostridium difficile infections. Several candidates are in advanced clinical stages.
DelveInsight, a business analysis firm, released a report on Tuesday detailing the landscape of research and development for Clostridium difficile (C. difficile) infection treatments.
The report identifies more than 20 companies actively pursuing the development of over 22 pipeline drug candidates for C. difficile infections. These candidates range from preclinical stages to advanced clinical trials.
Vedanta Biosciences is noted as having the most advanced candidate, VE303, which has reached Phase III clinical trials. This oral therapeutic is designed to prevent recurrence of C. difficile infections.
Other key companies involved in this development space include Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, and Finch Therapeutics Group. The research focuses on novel antibiotics, microbiome-based therapies, and antibodies targeting the bacterium's severe intestinal effects.